Cargando…

Adoptive T-cell therapy: adverse events and safety switches

The potential of adoptive T-cell therapy in effecting complete and durable responses has been demonstrated in a number of malignant and infectious diseases. Ongoing progress in T-cell engineering has given cause for optimism in the broader clinical applicability of this approach. However, the develo...

Descripción completa

Detalles Bibliográficos
Autor principal:	Tey, Siok-Keen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232067/ https://www.ncbi.nlm.nih.gov/pubmed/25505965 http://dx.doi.org/10.1038/cti.2014.11

Ejemplares similares

Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation
por: Zhang, Ping, et al.
Publicado: (2019)

Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation
por: Tey, Siok-Keen, et al.
Publicado: (2022)

Host immune system strikes back: Autophagy-mediated antigen presentation bypasses viral blockade of the classic MHC class I processing pathway
por: Tey, Siok-Keen, et al.
Publicado: (2012)

Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation
por: Ullah, Md Ashik, et al.
Publicado: (2016)

PET assessment of acute gastrointestinal graft versus host disease
por: Scott, Ashleigh P., et al.
Publicado: (2023)

Nanopore sequencing as a scalable, cost-effective platform for analyzing polyclonal vector integration sites following clinical T cell therapy
por: Zhang, Ping, et al.
Publicado: (2020)

CAR T-Cell Therapy: Adverse Events and Management
por: Adkins, Sherry
Publicado: (2019)

Adverse Events in NMOSD Therapy
por: Giglhuber, Katrin, et al.
Publicado: (2022)

Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events
por: Gu, Stephanie L., et al.
Publicado: (2023)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Adoptive T-cell therapy for Leukemia
por: Garber, Haven R, et al.
Publicado: (2014)

Adoptive Cell Therapy for T-Cell Malignancies
por: Fang, Karen Kai-Lin, et al.
Publicado: (2022)

Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events
por: Arn, Courtney R., et al.
Publicado: (2023)

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy
por: Vani, Vanina, et al.
Publicado: (2020)

Adverse events of targeted therapies approved for women's cancers
por: Saint-Ghislain, Mathilde, et al.
Publicado: (2021)

Reporting of adverse events for marketed drugs: Need for strengthening safety database
por: Apte, Aditi Anand
Publicado: (2016)

Adoptive T-cell therapy for Hodgkin lymphoma
por: Ho, Carrie, et al.
Publicado: (2021)

Adverse Events of Auricular Therapy: A Systematic Review
por: Tan, Jing-Yu, et al.
Publicado: (2014)

Adverse Events of Monoclonal Antibodies Used for Cancer Therapy
por: Guan, Mei, et al.
Publicado: (2015)

Management of adverse events related to checkpoint inhibition therapy
por: Rudzki, Jakob Daniel
Publicado: (2018)

Challenges and new technologies in adoptive cell therapy
por: Zhang, Pengchao, et al.
Publicado: (2023)

Managing the adverse events of intravesical bacillus Calmette–Guérin therapy
por: Decaestecker, Karel, et al.
Publicado: (2015)

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
por: Fleischmann, Roy, et al.
Publicado: (2020)

Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
por: Lee, Chae Won, et al.
Publicado: (2022)

Regulatory T Cells in Atherosclerosis: Is Adoptive Cell Therapy Possible?
por: Churov, Alexey V., et al.
Publicado: (2023)

Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
por: Yang, Chieh, et al.
Publicado: (2023)

Adverse events, side effects and complications in mesenchymal stromal cell-based therapies
por: Baranovskii, Denis S., et al.
Publicado: (2022)

Laser-Assisted Drug Delivery: A Systematic Review of Safety and Adverse Events
por: Ng, William Hao Syuen, et al.
Publicado: (2022)

Development of a TGFβ—IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy
por: Beck, Carole, et al.
Publicado: (2023)

Possible adverse events in children treated by manual therapy: a review
por: Humphreys, B Kim
Publicado: (2010)

Adverse events associated with paediatric massage therapy: a systematic review
por: Karkhaneh, Mohammad, et al.
Publicado: (2020)

Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
por: Pozzi, Samantha, et al.
Publicado: (2021)

The Past, Present, and Future of Adoptive T Cell Therapy
por: Choi, Donghoon, et al.
Publicado: (2012)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy
por: Yee, Cassian
Publicado: (2005)

Adoptive T-cell therapy for fungal infections in haematology patients
por: Deo, Shivashni S, et al.
Publicado: (2015)

Immune correlates of melanoma survival in adoptive cell therapy
por: Lee, Agnes Fermin, et al.
Publicado: (2013)

Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy
por: Garcia-Aponte, Oscar Fabian, et al.
Publicado: (2021)

Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology
por: Huang, Weize, et al.
Publicado: (2022)

The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events
por: Sakata, Yoshihiko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vnj43917p6hbr0oboq5ij1vom9